期刊文献+

诺和锐三餐前注射联合DPP4抑制剂强化治疗2型糖尿病疗效观察 被引量:2

在线阅读 下载PDF
导出
摘要 120例2型糖尿病患者分为观察组和对照组,对照组于每日早、中、晚餐前15min注射诺和锐30,观察组在对照组的基础上给予口服沙格列汀,观察两组患者临床疗效,并对比分析治疗前后空腹血糖(FPG)、空腹胰岛素(FINS)、糖化血红蛋白(HbAlc)、三餐后2h血糖等指标的变化。观察组显效36例,有效率20例,无效4例,发生低血糖4例,总有效率为93.33%,低血糖发生率为6.67%,对照组显效27例,有效23例,无效10例,发生低血糖8例,总有效率为83.33%,低血糖发生率为13.33%,观察组临床疗效明显优于对照组,P<0.05差异有统计学意义;治疗后两组患者的腹血糖(FPG)、糖化血红蛋白(HbAlc)、三餐后2h血糖及血液流变学各项指标较治疗前均有所下降,观察组下降幅度明显较对照组大,P<0.05差异有统计学意义。DPP4抑制剂联合胰岛素对2型糖尿病进行治疗可有效控制血糖,同时能改善胰岛功能,降低低血糖的发生率。
作者 李经
出处 《现代诊断与治疗》 CAS 2015年第7期1491-1493,共3页 Modern Diagnosis and Treatment
  • 相关文献

参考文献6

二级参考文献35

  • 1Goke B.Islet cell function:alpha and beta cells-partners towards normoglycaemia.Int J Clin Pract Suppl,2008,(159):2-7.
  • 2Kim MH,Lee MK.The incretins and pancreatic beta-cells:use of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide to cure type 2 diabetes Mellitus.Korean Diabetes J,2010,34:2-9.
  • 3Kim W,Egan JM.The role of incretins in glucose homeostasis and diabetes treatment.Pharmacol Rev,2008,60:470-512.
  • 4Neumiller JJ,Wood L,Campbell RK.Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus.Pharmacotherapy,2010,30:463-484.
  • 5Deacon CF.Circulation and degradation of GIP and GLP-1.Horm Metab Res,2004,36:761-765.
  • 6Deacon CF,Carr RD,Holst JJ.DPP-4 inhibitor therapy:new directions in the treatment of type 2 diabetes.Front Biosci,2008,13:1780-1794.
  • 7Lankas GR,Leiting B,Roy RS,et al.Dipeptidyl peptidase Ⅳ inhibition for the treatment of type 2 diabetes:potential importance of selectivity over dipeptidyl peptidases 8 and 9.Diabetes,2005,54:2988 -2994.
  • 8Holst JJ,Deacon CF.Inhibition of the activity of dipeptidyl-peptidase Ⅳ as a treatment for type 2 diabetes.Diabetes,1998,47:1663-1670.
  • 9Ahren B,Holst JJ,Martensson H,et al.Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase Ⅳ in mice.Eur J Pharmacol,2000,404:239-245.
  • 10Mari A,Sallas WM,He YL,et al.Vildagliptin,a dipeptidyl peptidase-Ⅳ inhibitor,improves model-assessed beta-cell function in patients with type 2 diabetes.J Clin Endocrinol Metab,2005,90:4888-4894.

共引文献86

同被引文献15

  • 1Bolli GB, et al. The "dawn phenomenon "-a common oc- cunence in both non-insulin-dependent and insulin-dependent diabetes mellitus NEnglJ Med 1981;310:746.
  • 2Muis M J, Bots ML, Bilo HI, et al. High cumulative insulin exposure : a risk factor of atherosclerosis in type 1 diabetes? Atheroscle- rosis 2005 ; 181 : 185.
  • 3Charbonnel B, DeFronzo R, Davidson J, et al. Pioglitazone use in combination with insulin in the prospective pioglitazone clinical trial in macrovascular events study (PROactivel9). J Clin Endocrinol Metab 2010 ;95:216.
  • 4Drucker DJ. The biology of incretin hormones. Cell Metab 2006 ;3 : 153-165.
  • 5Anthony H. Barnett,et al. Sitagliptin add-on therapy to insulin with or without metformin for type2 diabetes meUitus:52-week safety and efficancy. Clinical Drug Investing 2013 ;33:707-717.
  • 6Matthew L Mintz, Gianmaria Minervini, et al. Sitagliptin ver- sus glipizide as add-on therapy to metformin : assesment of hypoglyce- mia 2014;30(5) :761-770.
  • 7Haesuk Park, Chanhyun Park. et al. The Annals of Pharmaco- therapy 2012;11(46) :1453-1469.
  • 8王结胜,葛星,王钦贤.西格列汀治疗老年2型糖尿病患者的临床观察[J].中国药物与临床,2012,12(3):375-376. 被引量:9
  • 9杨松,谷媛媛,李兆亮,杨杰,亓文波,管庆波.沙格列汀或格列美脲联合甘精胰岛素对2型糖尿病患者血糖波动影响的观察[J].中国糖尿病杂志,2015,23(3):237-240. 被引量:61
  • 10周玥,何梅,杨明,刘福.GLP-1受体激动剂与DPP-4抑制剂比较治疗2型糖尿病效果的系统评价[J].中国循证医学杂志,2014,14(12):1459-1466. 被引量:16

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部